Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Author(s): Steven Tucker

Volume 11, Issue 1, 2010

Page: [58 - 60] Pages: 3

DOI: 10.2174/138945010790031036

Price: $65

Abstract

Despite improvements in first-line therapy for advanced NSCLC all patients with metastatic disease will progress at some point. Patients with favorable prognostic factors such as good performance status, non-squamous histology, stable weight, and perhaps female gender are more likely to receive second-line chemotherapy. Currently the United States FDA recognizes three single agents (docetaxel, erlotinib, and pemetrexed) as established for providing a benefit in patients who have experienced progression after first-line therapy. This review focuses on the role of PEM in the treatment of advanced NSCLC in patients who have experienced disease progression during or after first-line therapy. The multi-targeted antifolate pemetrexed is equivalent to docetaxel for second-line therapy and with less toxicity.

Keywords: Advanced non-small cell lung cancer, second-line chemotherapy, pemetrexed


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy